C122P: Benralizumab Biosimilar, Human IL-5Ra Monoclonal Antibody

Catalog No.: C122P | **Product Name:** Benralizumab Biosimilar, Human IL-5Ra Monoclonal Antibody

The research grade Benralizumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

PRODUCT SPECIFICATIONS

Catalog No.	C122P
Product Name	Benralizumab Biosimilar, Human IL-5Ra Monoclonal Antibody
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	CD125; CDw125CD125; HSIL5R3; IL-5 R alpha; IL-5R subunit alpha; IL5R; IL5RA; IL-5Ra; MGC26560
Summary	Recombinant Humanized IgG1 Monoclonal Antibody.
Isotype	Human IgG1 kappa.
Source/Host	The anti-human IL-5 R alpha/CD125 monoclonal antibody benralizumab biosimilar was produced in mammalian cells.
Specificity/Sensitivity	The in vivo grade benralizumab biosimilar specifically binds to the IL-5 R alpha/CD125 protein.
Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by benralizumab.
Form Of Antibody	0.2 μM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The Benralizumab Biosimilar, Human IL-5Ra Monoclonal Antibody is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	The research grade Benralizumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

REFERENCES & BACKGROUND

What is benralizumab biosimilar research grade? Benralizumab (trade name Fasenra) is a humanized afucosylated IgG1 monoclonal antibody that targets the alpha subunit of the interleukin-5 receptor (IL-5Rα / CD125) expressed on the surface of eosinophils and basophils. By binding to IL-5Rα, benralizumab induces antibody-dependent cell-mediated cytotoxicity (ADCC), leading to rapid and near-complete depletion of eosinophils. Benralizumab is indicated for the add-on maintenance treatment of severe asthma with an eosinophilic phenotype in adult and pediatric patients aged 6 years and older, and for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA). Benralizumab biosimilar uses the same protein sequences as the therapeutic antibody benralizumab.